The University of Chicago Header Logo

Connection

James Vardiman to CD4-CD8 Ratio

Back to Details
This is a "connection" page, showing publications James Vardiman has written about CD4-CD8 Ratio.
James Vardiman
Connection Strength
0.008
CD4-CD8 Ratio
  1. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.